Development of wheat with hypoimmunogenic gluten obstructed by the gene editing policy in europe

Aurélie Jouanin, Lesley Boyd, Richard G.F. Visser, Marinus J.M. Smulders

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Scopus)

Abstract

Coeliac Disease (CD) is an auto-immune reaction to gluten in 1–2% of the human population. A gluten-free (GF) diet, excluding wheat, barley, and rye, is the only remedy. This diet is difficult to adhere to, partly because wheat gluten is added to many processed products for their viscoelastic properties. In addition, GF products are less healthy and expensive. Wheat products containing only hypoimmunogenic gluten proteins would be a desirable option. Various gluten peptides that trigger CD have been characterized. A single wheat variety contains around hundred gluten genes, producing proteins with varying numbers of epitopes. Gene editing using CRISPR/Cas9 can precisely remove or modify the DNA sequences coding for immunogenic peptides. Wheat with hypoimmunogenic gluten thus exemplifies the potential of gene editing for improving crops for human consumption where conventional breeding cannot succeed. We describe here, in relation to breeding hypoimmunogenic wheat varieties, the inconsistencies of applying GM regulation in Europe for gene-edited plants while mutation breeding-derived plants are exempted. We explain that healthy products derived from this new technology may become available in the United States, Canada, Argentina and other countries but not in Europe, because of strict regulation of unintended GM risk at the expense of reduction the existing immunogenicity risks of patients. We argue that regulation of gene-edited plants should be based on scientific evidence. Therefore, we strongly recommend implementing the innovation principle. Responsible Research and Innovation, involving stakeholders including CD patient societies in the development of gene-editing products, will enable progress toward healthy products and encourage public acceptance.

Original languageEnglish
Article number1523
JournalFrontiers in Plant Science
Volume871
DOIs
Publication statusPublished - 18 Oct 2018

Fingerprint

gluten
Genes
wheat
celiac disease
genes
Nutrition
Peptides
breeding
Innovation
Antigen-antibody reactions
peptides
wheat products
gluten-free diet
Proteins
Epitopes
wheat gluten
DNA sequences
processed foods
automobiles
human population

Keywords

  • Coeliac disease
  • Genetic modification
  • GM regulation
  • Innovation principle
  • Mutation breeding
  • New plant breeding technique
  • Public acceptance
  • Risk assessment

Cite this

@article{8cc54feb5558426eaf45e7c8db85b77c,
title = "Development of wheat with hypoimmunogenic gluten obstructed by the gene editing policy in europe",
abstract = "Coeliac Disease (CD) is an auto-immune reaction to gluten in 1–2{\%} of the human population. A gluten-free (GF) diet, excluding wheat, barley, and rye, is the only remedy. This diet is difficult to adhere to, partly because wheat gluten is added to many processed products for their viscoelastic properties. In addition, GF products are less healthy and expensive. Wheat products containing only hypoimmunogenic gluten proteins would be a desirable option. Various gluten peptides that trigger CD have been characterized. A single wheat variety contains around hundred gluten genes, producing proteins with varying numbers of epitopes. Gene editing using CRISPR/Cas9 can precisely remove or modify the DNA sequences coding for immunogenic peptides. Wheat with hypoimmunogenic gluten thus exemplifies the potential of gene editing for improving crops for human consumption where conventional breeding cannot succeed. We describe here, in relation to breeding hypoimmunogenic wheat varieties, the inconsistencies of applying GM regulation in Europe for gene-edited plants while mutation breeding-derived plants are exempted. We explain that healthy products derived from this new technology may become available in the United States, Canada, Argentina and other countries but not in Europe, because of strict regulation of unintended GM risk at the expense of reduction the existing immunogenicity risks of patients. We argue that regulation of gene-edited plants should be based on scientific evidence. Therefore, we strongly recommend implementing the innovation principle. Responsible Research and Innovation, involving stakeholders including CD patient societies in the development of gene-editing products, will enable progress toward healthy products and encourage public acceptance.",
keywords = "Coeliac disease, Genetic modification, GM regulation, Innovation principle, Mutation breeding, New plant breeding technique, Public acceptance, Risk assessment",
author = "Aur{\'e}lie Jouanin and Lesley Boyd and Visser, {Richard G.F.} and Smulders, {Marinus J.M.}",
year = "2018",
month = "10",
day = "18",
doi = "10.3389/fpls.2018.01523",
language = "English",
volume = "871",
journal = "Frontiers in Plant Science",
issn = "1664-462X",
publisher = "Frontiers",

}

Development of wheat with hypoimmunogenic gluten obstructed by the gene editing policy in europe. / Jouanin, Aurélie; Boyd, Lesley; Visser, Richard G.F.; Smulders, Marinus J.M.

In: Frontiers in Plant Science, Vol. 871, 1523, 18.10.2018.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Development of wheat with hypoimmunogenic gluten obstructed by the gene editing policy in europe

AU - Jouanin, Aurélie

AU - Boyd, Lesley

AU - Visser, Richard G.F.

AU - Smulders, Marinus J.M.

PY - 2018/10/18

Y1 - 2018/10/18

N2 - Coeliac Disease (CD) is an auto-immune reaction to gluten in 1–2% of the human population. A gluten-free (GF) diet, excluding wheat, barley, and rye, is the only remedy. This diet is difficult to adhere to, partly because wheat gluten is added to many processed products for their viscoelastic properties. In addition, GF products are less healthy and expensive. Wheat products containing only hypoimmunogenic gluten proteins would be a desirable option. Various gluten peptides that trigger CD have been characterized. A single wheat variety contains around hundred gluten genes, producing proteins with varying numbers of epitopes. Gene editing using CRISPR/Cas9 can precisely remove or modify the DNA sequences coding for immunogenic peptides. Wheat with hypoimmunogenic gluten thus exemplifies the potential of gene editing for improving crops for human consumption where conventional breeding cannot succeed. We describe here, in relation to breeding hypoimmunogenic wheat varieties, the inconsistencies of applying GM regulation in Europe for gene-edited plants while mutation breeding-derived plants are exempted. We explain that healthy products derived from this new technology may become available in the United States, Canada, Argentina and other countries but not in Europe, because of strict regulation of unintended GM risk at the expense of reduction the existing immunogenicity risks of patients. We argue that regulation of gene-edited plants should be based on scientific evidence. Therefore, we strongly recommend implementing the innovation principle. Responsible Research and Innovation, involving stakeholders including CD patient societies in the development of gene-editing products, will enable progress toward healthy products and encourage public acceptance.

AB - Coeliac Disease (CD) is an auto-immune reaction to gluten in 1–2% of the human population. A gluten-free (GF) diet, excluding wheat, barley, and rye, is the only remedy. This diet is difficult to adhere to, partly because wheat gluten is added to many processed products for their viscoelastic properties. In addition, GF products are less healthy and expensive. Wheat products containing only hypoimmunogenic gluten proteins would be a desirable option. Various gluten peptides that trigger CD have been characterized. A single wheat variety contains around hundred gluten genes, producing proteins with varying numbers of epitopes. Gene editing using CRISPR/Cas9 can precisely remove or modify the DNA sequences coding for immunogenic peptides. Wheat with hypoimmunogenic gluten thus exemplifies the potential of gene editing for improving crops for human consumption where conventional breeding cannot succeed. We describe here, in relation to breeding hypoimmunogenic wheat varieties, the inconsistencies of applying GM regulation in Europe for gene-edited plants while mutation breeding-derived plants are exempted. We explain that healthy products derived from this new technology may become available in the United States, Canada, Argentina and other countries but not in Europe, because of strict regulation of unintended GM risk at the expense of reduction the existing immunogenicity risks of patients. We argue that regulation of gene-edited plants should be based on scientific evidence. Therefore, we strongly recommend implementing the innovation principle. Responsible Research and Innovation, involving stakeholders including CD patient societies in the development of gene-editing products, will enable progress toward healthy products and encourage public acceptance.

KW - Coeliac disease

KW - Genetic modification

KW - GM regulation

KW - Innovation principle

KW - Mutation breeding

KW - New plant breeding technique

KW - Public acceptance

KW - Risk assessment

U2 - 10.3389/fpls.2018.01523

DO - 10.3389/fpls.2018.01523

M3 - Article

VL - 871

JO - Frontiers in Plant Science

JF - Frontiers in Plant Science

SN - 1664-462X

M1 - 1523

ER -